Our findings with a relatively low frequency of HER2 amplified ovarian cancers makes the concept of HER2 testing as a routine screening in ovarian cancer less obvious as testing of Trastuzumab adjuvant therapy in a clinical trial would require a very large cohort to give sufficient power [10]. This evidence concerns the gene ERBB2 and ovarian cancer.